These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 8076351)
1. No association between c-myc amplification and TP53 mutation in sarcoma tumorigenesis. Castresana JS; Barrios C; Gómez L; Kreicbergs A Cancer Genet Cytogenet; 1994 Aug; 76(1):47-9. PubMed ID: 8076351 [TBL] [Abstract][Full Text] [Related]
2. Analysis of the c-myc, K-ras and p53 genes in methylcholanthrene-induced mouse sarcomas. Watanabe H; Shimokado K; Asahara T; Dohi K; Niwa O Jpn J Cancer Res; 1999 Jan; 90(1):40-7. PubMed ID: 10076563 [TBL] [Abstract][Full Text] [Related]
3. Detection of TP53 gene mutations in human sarcomas. Castresana JS; Rubio MP; Gómez L; Kreicbergs A; Zetterberg A; Barrios C Eur J Cancer; 1995; 31A(5):735-8. PubMed ID: 7640047 [TBL] [Abstract][Full Text] [Related]
4. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888 [TBL] [Abstract][Full Text] [Related]
5. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Imamura J; Bartram CR; Berthold F; Harms D; Nakamura H; Koeffler HP Cancer Res; 1993 Sep; 53(17):4053-8. PubMed ID: 8358734 [TBL] [Abstract][Full Text] [Related]
6. Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Crook T; Wrede D; Tidy J; Scholefield J; Crawford L; Vousden KH Oncogene; 1991 Jul; 6(7):1251-7. PubMed ID: 1650445 [TBL] [Abstract][Full Text] [Related]
8. TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma cell lines. Xu L; Davidson BJ; Murty VV; Li RG; Sacks PG; Garin-Chesa P; Schantz SP; Chaganti RS Int J Cancer; 1994 Nov; 59(3):383-7. PubMed ID: 7927946 [TBL] [Abstract][Full Text] [Related]
9. Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Grimm MO; Jürgens B; Schulz WA; Decken K; Makri D; Schmitz-Dräger BJ Urol Res; 1995; 23(5):293-300. PubMed ID: 8839385 [TBL] [Abstract][Full Text] [Related]
10. Mutation of the p53 gene in postradiation sarcoma. Nakanishi H; Tomita Y; Myoui A; Yoshikawa H; Sakai K; Kato Y; Ochi T; Aozasa K Lab Invest; 1998 Jun; 78(6):727-33. PubMed ID: 9645763 [TBL] [Abstract][Full Text] [Related]
11. No correlation of c-myc overexpression and p53 mutations in liposarcomas. Schneider-Stock R; Walter H; Rys J; Radig K; Hoang-Vu C; Roessner A Virchows Arch; 1998 Oct; 433(4):315-21. PubMed ID: 9808433 [TBL] [Abstract][Full Text] [Related]
12. Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma. Barrios C; Castresana JS; Ruiz J; Kreicbergs A J Orthop Res; 1993 Jul; 11(4):556-63. PubMed ID: 8101872 [TBL] [Abstract][Full Text] [Related]
13. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Berns EM; Klijn JG; Smid M; van Staveren IL; Look MP; van Putten WL; Foekens JA Genes Chromosomes Cancer; 1996 Jul; 16(3):170-9. PubMed ID: 8814449 [TBL] [Abstract][Full Text] [Related]
14. Genetic alterations of cancer-related genes in glass fiber-induced transformed cells. Whong WZ; Gao HG; Zhou G; Ong T J Toxicol Environ Health A; 1999 Mar; 56(6):397-404. PubMed ID: 10096362 [TBL] [Abstract][Full Text] [Related]
15. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708 [TBL] [Abstract][Full Text] [Related]
16. p53 gene mutations and abnormal retinoblastoma protein in radiation-induced human sarcomas. Brachman DG; Hallahan DE; Beckett MA; Yandell DW; Weichselbaum RR Cancer Res; 1991 Dec; 51(23 Pt 1):6393-6. PubMed ID: 1933904 [TBL] [Abstract][Full Text] [Related]
17. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891 [TBL] [Abstract][Full Text] [Related]
18. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877 [TBL] [Abstract][Full Text] [Related]
19. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408 [TBL] [Abstract][Full Text] [Related]
20. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Stratton MR; Moss S; Warren W; Patterson H; Clark J; Fisher C; Fletcher CD; Ball A; Thomas M; Gusterson BA Oncogene; 1990 Sep; 5(9):1297-301. PubMed ID: 2216456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]